187 related articles for article (PubMed ID: 35584767)
1. [Caffeine, Chocolate and Adenosine A2A Receptor Antagonists in the Treatment of Parkinson's Disease].
Reichmann H
Fortschr Neurol Psychiatr; 2023 Jun; 91(6):256-261. PubMed ID: 35584767
[TBL] [Abstract][Full Text] [Related]
2. Do caffeine and more selective adenosine A
Chen JF; Schwarzschild MA
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
[TBL] [Abstract][Full Text] [Related]
3. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
Petzer JP; Petzer A
Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641
[TBL] [Abstract][Full Text] [Related]
4. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
Cacciari B; Spalluto G; Federico S
Mini Rev Med Chem; 2018; 18(14):1168-1174. PubMed ID: 29692248
[TBL] [Abstract][Full Text] [Related]
5.
Boulaamane Y; Ibrahim MAA; Britel MR; Maurady A
J Integr Bioinform; 2022 Dec; 19(4):. PubMed ID: 36112816
[TBL] [Abstract][Full Text] [Related]
6. A
Lambertucci C; Marucci G; Catarzi D; Colotta V; Francucci B; Spinaci A; Varano F; Volpini R
Curr Med Chem; 2022 Aug; 29(28):4780-4795. PubMed ID: 35184706
[TBL] [Abstract][Full Text] [Related]
7. Targeting the adenosine A
Zhao Y; Zhou YG; Chen JF
Chin J Traumatol; 2024 May; 27(3):125-133. PubMed ID: 37679245
[TBL] [Abstract][Full Text] [Related]
8. Glutathione-Mediated Neuroprotective Effect of Purine Derivatives.
Matsumura N; Aoyama K
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685879
[TBL] [Abstract][Full Text] [Related]
9. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
Jenner P
Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
[TBL] [Abstract][Full Text] [Related]
10. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Chen JF
Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
[TBL] [Abstract][Full Text] [Related]
11. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Kalda A; Yu L; Oztas E; Chen JF
J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
[TBL] [Abstract][Full Text] [Related]
12. The role of istradefylline in the Parkinson's disease armamentarium.
Müller T
Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
[TBL] [Abstract][Full Text] [Related]
13. The Pharmacological Potential of Adenosine A
Mori A; Chen JF; Uchida S; Durlach C; King SM; Jenner P
Molecules; 2022 Apr; 27(7):. PubMed ID: 35408767
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
Schwarzschild MA; Xu K; Oztas E; Petzer JP; Castagnoli K; Castagnoli N; Chen JF
Neurology; 2003 Dec; 61(11 Suppl 6):S55-61. PubMed ID: 14663012
[TBL] [Abstract][Full Text] [Related]
15. A
Merighi S; Borea PA; Varani K; Vincenzi F; Jacobson KA; Gessi S
Curr Med Chem; 2022; 29(24):4138-4151. PubMed ID: 34844537
[TBL] [Abstract][Full Text] [Related]
16. Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.
Mori A
Int Rev Neurobiol; 2014; 119():87-116. PubMed ID: 25175962
[TBL] [Abstract][Full Text] [Related]
17. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.
Rivera-Oliver M; Díaz-Ríos M
Life Sci; 2014 Apr; 101(1-2):1-9. PubMed ID: 24530739
[TBL] [Abstract][Full Text] [Related]
18. Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease.
Morelli M
Exp Neurol; 2003 Nov; 184(1):20-3. PubMed ID: 14637073
[No Abstract] [Full Text] [Related]
19. Development of Adenosine A
Zheng J; Zhang X; Zhen X
ACS Chem Neurosci; 2019 Feb; 10(2):783-791. PubMed ID: 30199223
[TBL] [Abstract][Full Text] [Related]
20. Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease.
Kachroo A; Schwarzschild MA
Ann Neurol; 2012 Feb; 71(2):278-82. PubMed ID: 22367999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
